GIPR and type 2 diabetes mellitus: Drugs targeting GPCRs such as GLP-1RA, glucose-dependent insulinotropic polypeptide receptor (GIPR), and melanocortin-4 receptors (MC4R) have been approved for weight management and T2D (2, 3).